MediciNova, Inc. (MNOV) News
Filter MNOV News Items
MNOV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNOV News Highlights
- MNOV's 30 day story count now stands at 3.
- Over the past 26 days, the trend for MNOV's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE and NOV are the most mentioned tickers in articles about MNOV.
Latest MNOV News From Around the Web
Below are the latest news stories about MEDICINOVA INC that investors may wish to consider to help them evaluate MNOV as an investment opportunity.
The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitableLong term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning! |
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-OncologyLA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner Co |
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaLA JOLLA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its collaborator Genzyme Corporation, a subsidiary of Sanofi, has treated the first patient in a clinical trial of SAR444836 for the treatment of phenylketonuria (PKU). SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on a |
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in CanadaLA JOLLA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Once issued, the pa |
MediciNova Receives Gene Therapy Milestone PaymentLA JOLLA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therap |
MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model…By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Positive Results for MN-166 in Nonclinical Model of Chlorine Gas-Induced Lung Injury On September 27, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced results from the nonclinical studies conducted under its contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop MN-166 (ibudilast) |
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryLA JOLLA, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the results of the nonclinical studies conducted under its contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Servi |
MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury…By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Data Expected for MN-166 in GBM In January 2023, MediciNova, Inc. (NASDAQ:MNOV) announced that the Phase 2 trial of MN-166 (ibudilast) in combination with temozolomide (TMZ) for the treatment of glioblastoma (GBM) was fully enrolled ( NCT03782415 ). This is a two-part trial taking place at Dana-Farber Cancer |